Upcoming Earnings Overview:
GMAB is anticipated to report quarterly earnings on Wednesday, May 6th, with a consensus estimate EPS of $0.15.
Live Analysis:
Genmab A/S is currently priced at $26.54, experiencing a price decrease of 9.9999 cents (-0.375%) from the previous close. The trading volume is $429,932, representing a 26.41% increase compared to the average.
Performance Streak:
GMAB is amidst a three-day streak with a price decline of $1.15 (-4.15%) since starting at $27.69.
Earnings Overview:
In the latest quarterly report on Monday, February 16th, GMAB had a consensus estimate EPS of $0.46.
Cash Flow:
GMAB's free cash flow stands at $287.35 million, with a net change in cash of -$45.91 million.
Income Statement:
GMAB reported a gross profit of $974 million, operating income of $242.27 million, and a net income of $30.91 million.
Ratios:
Key ratios include a gross profit margin of 92.34%, return on equity of 0.53, and a price-earnings ratio of 1000.51.
Balance Sheet:
The company holds total assets of $12.84 billion, with total liabilities at $7 billion, and net debt at $3.71 billion.
This comprehensive overview provides insights into GMAB's recent performance and financial standing as it navigates market fluctuations and prepares for upcoming earnings announcements.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.